NCT01962103 - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

December 4, 2013

Primary Completion Date

December 5, 2017

Study Completion Date

November 6, 2018

Conditions

NeuroblastomaRhabdomyosarcomaEwing's SarcomaEwing's TumorSarcoma, Ewing'sSarcomas, EpitheliodSarcoma, Soft TissueSarcoma, Spindle CellMelanomaMalignant MelanomaClinical OncologyOncology, MedicalPediatrics, OsteosarcomaOsteogenic SarcomaOsteosarcoma TumorSarcoma, OsteogenicTumorsCancerNeoplasiaNeoplasmHistiocytomaFibrosarcomaDermatofibrosarcoma

Interventions

DRUG

nab-paclitaxel

nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle

DRUG

nab-paclitaxel

IV infusion

Trial Locations (20)

8032

Universitäts-Kinderklinik, Zurich

8035

Hospital Universitario Vall D Hebron, Barcelona

8950

Hospital Sant Joan de Deu, Barcelona

10032

Columbia University Medical Center, New York

10126

l'Azienda Ospedaliera Regina Margherita - Sant Anna, Torino

16147

Children's Hospital Largo, Genova

28029

Spanish National Cancer Research Centre, Madrid

35128

Clinica di Oncoematologia, Padua

41013

Hospital Universitario Virgen Del Rocio, Seville

46026

Unidad de Oncologia Pediatrica, Hospital Universitario la Fe, Valencia

50139

Azienda Ospedaliera Universitaria Meyer, Florence

54000

Hopital d'Enfants, CHU Nancy, Nancy

69008

Institute for Pediatric Hematology - Oncology, Leon Berard Cancer Center, Lyon

75005

Institut Curie, Paris

85016

Phoenix Childrens Hospital, Phoenix

94805

Institut Gustave Roussy, Villejuif

M5G 1X8

The Hospital for Sick Children, Toronto

Unknown

Istituto Nazionale Tumori, Milan

00168

Policlinico Agostino Gemelli, Rome

SM2 5PT

Royal Marsden Hospital, Sutton